FDA Update: Revised Implementation Timelines For Nitrosamine Impurities (June 23, 2025)

On June 23, 2025, the U.S. Food and Drug Administration issued an important update to its guidance on nitrosamine impurities in pharmaceuticals, specifically revising the Recommended Implementation Timelines (Table 4) on the CDER Nitrosamine Impurity Acceptable Intake Limits webpage.

This update reflects the FDA’s recognition that nitrosamine risk assessment, confirmatory testing, and mitigation strategies are complex, resource-intensive processes requiring additional time for full implementation.

FDA Nitrosamine Update 2025

The FDA’s June 2025 update extends timelines for nitrosamine impurity compliance, allowing companies to submit an NDSRI progress update by August 1, 2025, if full confirmatory testing and mitigation are not yet complete.

Nitrosamine Risk in Pharmaceuticals

Nitrosamines are potentially carcinogenic impurities that may form during:

• Drug manufacturing processes 
• Storage and degradation 
• Interaction of raw materials 

Their presence has led to global regulatory scrutiny, recalls, and stricter impurity control requirements.

Key Regulatory Change: Revised Timelines

Previously, companies were required to:

• Complete confirmatory testing 
• Submit CMC updates 

by August 1, 2025

What Has Changed?

If full implementation is not feasible, companies must now submit an:

NDSRI Progress Update (Nitrosamine Drug Substance-Related Impurity)

Updated FDA Expectations

What is the NDSRI Progress Update?

The NDSRI update is a regulatory submission detailing the status of nitrosamine risk assessment and mitigation efforts.

Submission Details

• Included in Annual Report (eCTD Section 1.13.14) 
• If already submitted → file a revision 
• Next annual reporting cycle remains unchanged 

What Must Be Included in the NDSRI Update

The FDA expects a comprehensive and scientifically justified update, including:

1. Nitrosamine Formation Assessment

• Results from forced degradation studies 
• Identification of potential formation pathways 

2. Detected Nitrosamines

• Specific nitrosamines identified 
• Quantification levels 

3. Analytical Method Validation

• Validated testing methods 
• Sensitivity and specific data 

4. Batch Testing Data

• Number of batches tested 
• Testing timelines 
• Lot-specific results 

5. Confirmatory Testing Results

• Reported in: 
  • ng/day 
  • ppm 

6. Root Cause Analysis

• Identification of source(s) of nitrosamines 
• Process or material-related risks 

7. Mitigation Strategies

• Process modifications 
• Reformulation approaches 
• Supplier controls 

8. Implementation Timeline

• Estimated completion dates 
• Milestones for compliance 

Important Note

If any information is unavailable, companies must provide:

• Scientific justification 
• Explanation for delays 

Special Considerations: Interim AI Limits

Companies using interim Acceptable Intake (AI) limits (Table 3) must also:

• Submit NDSRI updates 
• Support FDA evaluation of future AI revisions 

Scope: Non-Application Products

For products not requiring Annual Reports:

• Maintain complete documentation 
• Ensure readiness for FDA inspection 

Product Category Requirements

Scientific Updates in FDA Guidance

The June 2025 update also includes revisions to:

1. Acceptable Intake (AI) Limits

• Based on Carcinogenic Potency Categorization Approach (CPCA)
• Use of compound-specific or surrogate data 

2. Analytical Testing Requirements

• Advanced confirmatory testing methods 
• Improved sensitivity standards 

3. Safety Assessment Framework

• Updated risk evaluation approaches 
• Enhanced impurity control strategies 

What This Means for Pharmaceutical Companies

Shift in Regulatory Focus

• From deadline-driven completion → progress-based transparency 

Key Implications

• August 1, 2025 is now a reporting milestone, not final compliance deadline 
• Companies must demonstrate: 
  • Active risk management 
  • Ongoing mitigation efforts 
• FDA will reassess timelines based on submitted data 

Action Plan for Compliance

Before August 1, 2025

1. Conduct Nitrosamine Risk Assessment

• Review of all products and processes 

2. Validate Analytical Methods

• Ensure robust detection capabilities 

3. Prepare NDSRI Update

• Compile testing, risk, and mitigation data 

4. Submit via Annual Report

• Include in eCTD 1.13.14 
• Revise submission if already filed 

5. Maintain Documentation

• Ensure audit readiness for all products 

Compliance Checklist

Industry Challenges

• Complex impurity formation pathways 
• High cost of testing and validation 
• Data gaps in legacy products 
• Supply chain variability 
• Tight regulatory timelines 

Outlook

The FDA’s revised approach signals:

• Greater flexibility in compliance with timelines 
• Increased reliance on scientific justification and transparency 
• Continued evolution of nitrosamine guidance 

Expected Trends

• More refined AI limits 
• Advanced analytical technologies 
• Stronger global harmonization 

Nitrosamine Compliance Expertise

Maven Regulatory Solutions provides specialized support in nitrosamine risk assessment, impurity control, and regulatory submissions.

Global Regulatory Experience

Our expertise includes:

• FDA, EMA, and global impurity guidelines 
• CMC documentation and lifecycle management 
• Risk-based compliance strategies 

Scientific Authority

Our team includes:

• Toxicologists and analytical experts 
• CMC specialists 
• Regulatory affairs professionals 

Trusted Compliance Partner

We assure you:

• Accurate impurity risk assessments 
• Timely regulatory submissions 
• Transparent communication with authorities 
• End-to-end compliance support 

Ensure Nitrosamine Compliance Partner with Maven Regulatory Solutions

Need support with FDA nitrosamine requirements?

We will help you.

• Conduct risk assessments and root cause analysis 
• Develop mitigation and control strategies 
• Prepare NDSRI updates and regulatory submissions 
• Ensure global compliance 

Our Services

• Nitrosamine risk evaluation 
• Analytical method validation 
• CMC documentation support 
• Regulatory submission strategy 
• Post-approval lifecycle management 

Why Choose Maven

• Deep expertise in impurity regulations 
• Strong FDA compliance knowledge 
• Scientific and regulatory integration 
• Proven track record 

Conclusion

The FDA’s June 2025 update introduces a pragmatic, risk-based approach to managing nitrosamine impurities.

By shifting focus to progress updates and transparency, the agency enables companies to:

• Continue mitigation efforts 
• Maintain compliance 
• Protect patient safety 

The NDSRI Progress Update serves as a critical bridge between ongoing assessment and full implementation.

Companies that act early, document thoroughly, and communicate transparently will be best positioned for regulatory success.

FAQs

1. What is the FDA nitrosamine update 2025?

A revision of timelines requiring progress updates instead of full compliance by August 1, 2025.

2. What is NDSRI?

Nitrosamine Drug Substance-Related Impurity progress update.

3. Where should the update be submitted?

In the Annual Report under eCTD Section 1.13.14.

4. Are timelines extended?

Yes, full implementation timelines will be updated later.

5. What are AI limits?

Acceptable intake limits for nitrosamine impurities.

6. What if data is incomplete?

Provide scientific justification and explanation.

7. How can Maven help?

By supporting risk assessment, testing, and regulatory submissions.